222 related articles for article (PubMed ID: 21888556)
1. Entinostat for treatment of solid tumors and hematologic malignancies.
Knipstein J; Gore L
Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
[TBL] [Abstract][Full Text] [Related]
2. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies of histone deacetylase inhibitors.
Prince HM; Bishton MJ; Harrison SJ
Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors in lymphoma and solid malignancies.
Rasheed W; Bishton M; Johnstone RW; Prince HM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):413-32. PubMed ID: 18366289
[TBL] [Abstract][Full Text] [Related]
5. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Batlevi CL; Kasamon Y; Bociek RG; Lee P; Gore L; Copeland A; Sorensen R; Ordentlich P; Cruickshank S; Kunkel L; Buglio D; Hernandez-Ilizaliturri F; Younes A
Haematologica; 2016 Aug; 101(8):968-75. PubMed ID: 27151994
[TBL] [Abstract][Full Text] [Related]
6. Entinostat for the treatment of breast cancer.
Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
[TBL] [Abstract][Full Text] [Related]
7. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Boumber Y; Younes A; Garcia-Manero G
Expert Opin Investig Drugs; 2011 Jun; 20(6):823-9. PubMed ID: 21554162
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat in lymphoid and myeloid malignancies.
Khot A; Dickinson M; Prince HM
Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641
[TBL] [Abstract][Full Text] [Related]
9. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Slingerland M; Guchelaar HJ; Gelderblom H
Anticancer Drugs; 2014 Feb; 25(2):140-9. PubMed ID: 24185382
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors: a patent review (2009 - 2011).
Carafa V; Miceli M; Altucci L; Nebbioso A
Expert Opin Ther Pat; 2013 Jan; 23(1):1-17. PubMed ID: 23094822
[TBL] [Abstract][Full Text] [Related]
17. The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.
Liu HB; Mayes PA; Perlmutter P; McKendrick JJ; Dear AE
Int J Oncol; 2011 May; 38(5):1421-5. PubMed ID: 21253674
[TBL] [Abstract][Full Text] [Related]
18. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
19. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Tellez CS; Grimes MJ; Picchi MA; Liu Y; March TH; Reed MD; Oganesian A; Taverna P; Belinsky SA
Int J Cancer; 2014 Nov; 135(9):2223-31. PubMed ID: 24668305
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]